Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

6.8K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.0K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

6.8K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

8.5K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.5K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

9.6K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.6K
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Tumor Subtype Defines Distinct Pathways Of Molecular And Clinical Progression In Primary Prostate Cancer.
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Tumor Subtype Defines Distinct Pathways Of Molecular And Clinical Progression In Primary Prostate Cancer.

Related Experiment Video

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
07:34

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

909

Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer.

Deli Liu1,2,3,4, Michael A Augello1,2, Ivana Grbesa1,2

  • 1Sandra and Edward Meyer Cancer Center and.

The Journal of Clinical Investigation
|May 17, 2021

View abstract on PubMed

Summary
This summary is machine-generated.

Prostate cancer progression varies by genomic subtype, with specific late-stage alterations like PTEN or CHD1 deletions impacting outcomes differently. Understanding these distinct molecular pathways is crucial for accurate clinical interpretation and management.

Keywords:
BioinformaticsGeneticsMolecular diagnosisOncology

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.4K
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.8K

Related Experiment Videos

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
07:34

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

909
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.4K
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.8K

Area of Science:

  • Oncology
  • Genomics
  • Molecular Biology

Background:

  • Prostate cancer (PCa) molecular subtypes arise from early genomic alterations.
  • The influence of these early changes on later molecular events and disease course is not fully understood.

Purpose of the Study:

  • To investigate the molecular and clinical progression of distinct prostate cancer genomic subtypes.
  • To define early and late molecular subclassifications and their impact on disease trajectory.

Main Methods:

  • Utilized human genomic and transcriptomic data to develop tumor lineage models.
  • Defined "early" and "late" molecular subclasses in 8,158 PCa patients using transcriptional classifiers.
  • Correlated molecular subclasses with clinical outcomes and pathologic characteristics via Kaplan-Meier and logistic regression.
Prostate cancer

Main Results:

  • Identified PTEN alterations in ERG-overexpressing (ERG+) and CHD1 alterations in SPOP-mutant tumors as subtype-specific late events.
  • Defined two distinct progression models: ERG/PTEN and SPOP/CHD1, sharing early tumorigenesis but diverging in progression pathways.
  • Found late events in ERG+ and SPOP-mutant subtypes associated with worse prognosis.
  • Observed distinct clinical features: PTEN deletions linked to higher locoregional stage, CHD1 deletions to increased grade, with similar metastatic potential.

Conclusions:

  • Prostate cancer subtypes exhibit distinct molecular and clinical progression pathways.
  • Tumor lineage influences the interpretation of clinical parameters like locoregional stage.
  • These findings may impact prostate cancer management decisions.